Attached files
| file | filename |
|---|---|
| EX-32.2 - CERTIFICATION - RELMADA THERAPEUTICS, INC. | f10k2020ex32-2_relmada.htm |
| EX-32.1 - CERTIFICATION - RELMADA THERAPEUTICS, INC. | f10k2020ex32-1_relmada.htm |
| EX-31.2 - CERTIFICATION - RELMADA THERAPEUTICS, INC. | f10k2020ex31-2_relmada.htm |
| EX-31.1 - CERTIFICATION - RELMADA THERAPEUTICS, INC. | f10k2020ex31-1_relmada.htm |
| EX-10.61 - RELMADA THERAPEUTICS, INC., 2021 EQUITY INCENTIVE PLAN - RELMADA THERAPEUTICS, INC. | f10k2020ex10-61_relmada.htm |
| 10-K - ANNUAL REPORT - RELMADA THERAPEUTICS, INC. | f10k2020_relmadatherapeutic.htm |
Exhibit 23.1
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
We consent to the incorporation by reference in the Registration Statements of Relmada Therapeutics, Inc. on Form S-3 (File No. 333-245054), on Form S-3 (File No. 333-234262) and on Form S-3 (Post-Effective Amendment No. 1 to Forms S-1 [Files No. 333-229258 and 333-233228]) of our report dated March 24, 2021, with respect to our audits of the consolidated financial statements of Relmada Therapeutics, Inc. as of December 31, 2020, December 31, 2019 and June 30, 2019 and for the year ended December 31, 2020, the six months ended December 31, 2019 and the year ended June 30, 2019, which report is included in this Annual Report on Form 10-K of Relmada Therapeutics, Inc. for the year ended December 31, 2020.
/s/ Marcum llp
Marcum llp
Houston, Texas
March 24, 2021